First drug 'slows decline' in progressive MS
The first drug to slow the decline in patients with primary progressive multiple sclerosis has been reported at a conference. The disease affects nerves and leads to fatigue, muscle problems and loss of vision. Preliminary data from trials of 732 people showed that ocrelizumab slowed the onset of disability by 24% over the course of 12 weeks.